Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates - PubMed (original) (raw)
Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates
N Sullivan et al. J Virol. 1995 Jul.
Abstract
The structure, replicative properties, and sensitivity to neutralization by soluble CD4 and monoclonal antibodies were examined for molecularly cloned envelope glycoproteins derived from human immunodeficiency virus type 1 (HIV-1) viruses either isolated directly from patients or passaged in T-cell lines. Complementation of virus entry into peripheral blood mononuclear cell targets by primary patient envelope glycoproteins exhibited efficiencies ranging from that observed for the HXBc2 envelope glycoproteins, which are derived from a T-cell line-passaged virus, to approximately fivefold-lower values. The ability of the envelope glycoproteins to complement virus entry roughly correlated with sensitivity to neutralization by soluble CD4. Laboratory-adapted viruses were sensitive to neutralization by monoclonal antibodies directed against the CD4-binding site and the third variable (V3) loop of the gp120 glycoprotein. By comparison, viruses with envelope glycoproteins from primary patient isolates exhibited decreased sensitivity to neutralization by these monoclonal antibodies; for these viruses, neutralization sensitivity correlated with replicative ability. Subinhibitory concentrations of soluble CD4 and a CD4-binding site-directed antibody significantly enhanced the entry of viruses containing envelope glycoproteins from some primary patient isolates. The sensitivity of viruses containing the different envelope glycoproteins to neutralization by soluble CD4 or monoclonal antibodies could be predicted by assays dependent on the binding of the inhibitory molecule to the oligomeric envelope glycoprotein complex but less well by assays measuring binding to the monomeric gp120 glycoprotein. These results indicate that the intrinsic structure of the oligomeric envelope glycoprotein complex of primary HIV-1 isolates, while often less than optimal with respect to the mediation of early events in virus replication, allows a relative degree of resistance to neutralizing antibodies. The interplay of selective forces for higher virus replication efficiency and resistance to neutralizing antibodies could explain the temporal course described for the in vivo emergence of HIV-1 isolates with differing phenotypes.
Similar articles
- Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
Sullivan N, Sun Y, Binley J, Lee J, Barbas CF 3rd, Parren PW, Burton DR, Sodroski J. Sullivan N, et al. J Virol. 1998 Aug;72(8):6332-8. doi: 10.1128/JVI.72.8.6332-6338.1998. J Virol. 1998. PMID: 9658072 Free PMC article. - CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, Sodroski J. Sullivan N, et al. J Virol. 1998 Jun;72(6):4694-703. doi: 10.1128/JVI.72.6.4694-4703.1998. J Virol. 1998. PMID: 9573233 Free PMC article. - Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Roben P, et al. J Virol. 1994 Aug;68(8):4821-8. doi: 10.1128/JVI.68.8.4821-4828.1994. J Virol. 1994. PMID: 7518527 Free PMC article. - Increased envelope spike density and stability are not required for the neutralization resistance of primary human immunodeficiency viruses.
Karlsson GB, Gao F, Robinson J, Hahn B, Sodroski J. Karlsson GB, et al. J Virol. 1996 Sep;70(9):6136-42. doi: 10.1128/JVI.70.9.6136-6142.1996. J Virol. 1996. PMID: 8709238 Free PMC article. - Candidate antibody-based therapeutics against HIV-1.
Gong R, Chen W, Dimitrov DS. Gong R, et al. BioDrugs. 2012 Jun 1;26(3):143-62. doi: 10.2165/11631400-000000000-00000. BioDrugs. 2012. PMID: 22462520 Free PMC article. Review.
Cited by
- The role of antibody-dependent enhancement in dengue vaccination.
Aynekulu Mersha DG, van der Sterren I, van Leeuwen LPM, Langerak T, Hakim MS, Martina B, van Lelyveld SFL, van Gorp ECM. Aynekulu Mersha DG, et al. Trop Dis Travel Med Vaccines. 2024 Nov 1;10(1):22. doi: 10.1186/s40794-024-00231-2. Trop Dis Travel Med Vaccines. 2024. PMID: 39482727 Free PMC article. - Antiviral neutralizing antibodies: from in vitro to in vivo activity.
Burton DR. Burton DR. Nat Rev Immunol. 2023 Nov;23(11):720-734. doi: 10.1038/s41577-023-00858-w. Epub 2023 Apr 17. Nat Rev Immunol. 2023. PMID: 37069260 Free PMC article. Review. - MiRNA-103 downmodulates CCR5 expression reducing human immunodeficiency virus type-1 entry and impacting latency establishment in CD4+ T cells.
Bellini N, Lodge R, Pham TNQ, Jain J, Murooka TT, Herschhorn A, Bernard NF, Routy JP, Tremblay CL, Cohen ÉA. Bellini N, et al. iScience. 2022 Sep 28;25(10):105234. doi: 10.1016/j.isci.2022.105234. eCollection 2022 Oct 21. iScience. 2022. PMID: 36267915 Free PMC article. - Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice.
Alzua GP, Pihl AF, Offersgaard A, Duarte Hernandez CR, Duan Z, Feng S, Fahnøe U, Sølund C, Weis N, Law M, Prentoe JC, Christensen JP, Bukh J, Gottwein JM. Alzua GP, et al. Gut. 2023 Mar;72(3):560-572. doi: 10.1136/gutjnl-2021-326323. Epub 2022 Aug 2. Gut. 2023. PMID: 35918103 Free PMC article. - CD8 Effector T Cells Function Synergistically With Broadly Neutralizing Antibodies to Enhance Suppression of HIV Infection.
Veenhuis RT, Garliss CC, Bailey JR, Blankson JN. Veenhuis RT, et al. Front Immunol. 2021 Jul 29;12:708355. doi: 10.3389/fimmu.2021.708355. eCollection 2021. Front Immunol. 2021. PMID: 34394110 Free PMC article.
References
- J Virol. 1994 Sep;68(9):6006-13 - PubMed
- J Virol. 1992 Jan;66(1):235-43 - PubMed
- J Acquir Immune Defic Syndr. 1992;5(3):303-7 - PubMed
- Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1335-9 - PubMed
- Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2223-6 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials